SsangYong Motor Co. employees have begun taking rotational unpaid leaves as part of self-help measures.
The two-year rotational unpaid leave, which is an extension of a wage cut and suspended welfare benefits until June 2023, was agreed upon between the company and its workers last month.
The arrangement is for 50 percent of assembly line workers in the Pyeongtaek plant, and 30 percent of office workers taking turns going on unpaid leave through June 2022.
The SUV-focused carmaker has a workforce of 4,590 as of Monday, consisting of 3,190 on the assembly line and 400 in the office.
The workers also agreed on Ssangyong's plan not to hire replacements to about 150 employees set to retire each year in the next five years.
SsangYong has been in the debt-rescheduling process since April after its Indian parent Mahindra & Mahindra Ltd. failed to attract investors.


Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
US Dollar Weakens as Yen Surges Amid Japan Intervention and Central Bank Moves
Panama Defends Port Takeover Amid U.S.-China Tensions and Canal Dispute
WTI Crude Oil Prices Rise Amid Iran Conflict Uncertainty
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
US-Iran Conflict Escalates Amid Oil Blockade and Rising Global Tensions
Asian Stocks Slip as Oil Prices Surge and Fed Signals Inflation Risks
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Oil Prices Slip Amid UAE’s OPEC Exit and Ongoing Iran Conflict Concerns
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand 



